Abstract
Background Amyotrophic lateral sclerosis (ALS), also known as Lou Gehriǵs disease, is a rare neurological disease and is the most common motor neurone disease. It is a fatal disease with specific loss of motor neurons in the spinal cord, brain stem, and motor cortex leading to progressive paralysis and usually death within five years of diagnosis. There remains no cure for ALS, and management is focused on a combination of neuroprotective medication, respiratory support, and management by multidisciplinary clinics.
Patients and Methods This prospective, single-arm, open-label phase II clinical trial of sustained weekly administration of 2 mg/kg ILB® (a low-molecular weight dextran sulphate) was conducted in a single UK hospital. Eligible patients were at least 18 years and had a definite diagnosis of ALS according to El Escorial Criteria. The co-primary outcomes were safety, tolerability, and quantity of ILB® administered. All evaluable patients were analysed in a modified intention-to-treat analysis.
EudraCT number. 2018-000668-28
Findings Between 18-Apr-2019 and 27-Mar-2020, 11 patients were recruited and treated for up to 38 weeks. There were no treatment terminations or withdrawals. One serious adverse event was reported, which was not related to ILB® and resolved without sequalae. 270 mild/moderate adverse events were reported with no intolerable events occurring during the trial. The total number of ILB® treatments administered per patient ranged from 4 to 38, with a cumulative dose ranging from 745 to 6668 mg. As a result of the COVID-19 pandemic and the high-risk status of study participants, recruitment and treatment was suspended early in Mar-2020. At the long-term follow-up, three patients had died after the trial was halted, between 53 and 62 weeks after their final ILB® injection.
Interpretation Long-term weekly ILB® injections of 2 mg/kg was well tolerated and had an acceptable safety profile in patients with ALS.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: AL and ZN are external consultants for Tikomed AB. AL is also a consultant for Axolotl Consulting Ltd. LB is an Executive Board Member and Inventor of ILB® at Tikomed AB. All other authors declare no competing interests.
Clinical Trial
EudraCT: 2018-000668-28; clinicaltrials.gov: NCT03705390
Funding Statement
Funding This trial was funded by a Tikomed AB grant, awarded to SPB, VS, DS and KB with the trial drug, ILB®, also given free of charge by Tikomed AB. Tikomed AB: https://www.tikomed.com/Sponsor: University of Birmingham - https://www.birmingham.ac.uk/research/crctu/index.aspx Role of the funding source The trial was initiated and conducted independently by the trial investigators. The funder, Tikomed AB, had no role in data collection, data analysis, or data interpretation. Tikomed AB reviewed this manuscript prior to submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the trial protocol (ultimately Version 8.0 dated 25-Nov-2020) was obtained from the South Central - Oxford B Research Ethics Committee (reference: 18/SC/0368) All patients gave written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Participant data and the associated supporting documentation will be available within six months after the publication of this manuscript. Details of our data request process is available on the CRCTU website. Only scientifically sound proposals from appropriately qualified research groups will be considered for data sharing. The decision to release data will be made by the CRCTU Director’s Committee, who will consider the scientific validity of the request, the qualifications and resources of the research group, the views of the Chief Investigator and the trial steering committee, consent arrangements, the practicality of anonymising the requested data and contractual obligations. A data sharing agreement will cover the terms and conditions of the release of trial data and will include publication requirements, authorship and acknowledgements and obligations for the responsible use of data. An anonymised encrypted dataset will be transferred directly using a secure method and in accordance with the University of Birmingham’s IT guidance on encryption of data sets.